⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BYSI News
BeyondSpring Inc. Ordinary Shares
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
globenewswire.com
BYSI
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
globenewswire.com
BYSI
Form 8-K
sec.gov
BYSI
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
BYSI
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
globenewswire.com
BYSI
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
globenewswire.com
BYSI
BeyondSpring Files 2025 Annual Report on Form 10-K
globenewswire.com
BYSI
Form 8-K
sec.gov
BYSI
BeyondSpring Reports 2025 Year-End Financial Results
globenewswire.com
BYSI
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
globenewswire.com
BYSI